Immune maladaptation in the etiology of preeclampsia: A review of corroborative epidemiologic studies

Obstetrical and Gynecological Survey

Volumn 53, Issue 6, 1998, Pages 377-382

  Dekker, Gustaaf A ^a   Robillard, P Y ^b   Hulsey, Thomas C ^b  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ARTIFICIAL INSEMINATION; EXPOSURE; FEMALE; HUMAN; IMMUNE SYSTEM; MALADJUSTMENT; MATERNAL HYPERTENSION; MULTIPARA; OOCYTE DONATION; PATERNITY; PREECLAMPSIA; PRIMIGRAVIDA; REVIEW; SPERM;

FEMALE; HUMANS; INSEMINATION, ARTIFICIAL, HETEROLOGOUS; MALE; OOCYTE DONATION; PARITY; PRE-ECLAMPSIA; PREGNANCY; SEXUAL PARTNERS; SPERMATOZOA;

EID: 0031835947     PISSN: 00297828     EISSN: None     Source Type: Journal    
DOI: 10.1097/00006254-199806000-00023     Document Type: Review

References (47)

1. Roberts JM, Redman CWG: Preeclampsia: More than pregnancy-induced hypertension. Lancet 1993;341:1447-1451.
2. Scott JR, Beer AA. Immunologic aspects of preeclampsia. Am J Obstet Gynecol 1976; 125: 418-427.
3. Mc Quarrie I. Isoagglutination in the new born infants and their mother: a possible relationship between interagglutination and the toxemias of pregnancy. John Hopkins Hosp Bull 1923; 34: 51-54.
4. Veit J. über Albuminurie in der Schwangerschaft. Ein Beitrag zur Physiologie der Schwangerschaft. Berl Klin Wochenschr 1902;3:513-516.
5. Medawar PB. Some immunological and endocrinological problems raised by the evolution of viviparity in vertebrates. In: Evolution 7. Society for Experimental Biology, Academic Press, New York, 1953, pp. 320-338.
6. Strickland DM, Guzick DS, Cox K et al. The relationship between abortion in the first pregnancy and development of pregnancy-induced hypertension in the subsequent pregnancy. Am J Obstet Gynecol 1986;154:146-148.
7. Need JA: Preeclampsia in pregnancies by different fathers. Br Med J 1975;2:548-549.
8. Feeney JG. Preeclampsia and changing paternity. In: Bonnar J, MacGillivray I, Symonds M, eds. Proceedings of the First Congress of the International Society for the Study of Hypertension in Pregnancy. MTP Press Ltd, 1980, pp 41-44.
9. Feeney JG, Scott JS. Preeclampsia and changed paternity. Eur J Obstet Gynecol Reprod Biol 1980;11:35-38.
10. Ikedife D. Eclampsia in multiparae. Br Med J 1980;280:985-986.
11. Robillard PY, Hulsey TC, Alexander GR et al. Paternity patterns and risk of preeclampsia in the last pregnancy in multiparae. J Reprod Immunol 1993;24:1-12.
12. Trupin LS, Simon LP, Eskenazi B. Change in paternity: A risk factor for preeclampsia in multiparas. Epidemiology 1996;7: 240-244.
13. Marti JJ, Herrmann U. Immunogestosis: A new etiologic concept of "essential" EPH gestosis, with special consideration of the primigravid patient. Am J Obstet Gynecol 1977;128:489-493.
14. Goecke C, Schwabe G. Vorschlag einer Stadien-Einteilung der Gestose. Zentralbl Gynaekol 1965;87:1439.
15. Klonoff-Cohen HS, Savitz DA, Cefalo RC et al. An epidemiologic study of contraception and preeclampsia. J Am Med Assoc 1989:262:3143-3147.
16. Mills JL, Klebanoff MA, Graubard BI et al. Barrier contraceptive methods and preeclampsia. J Am Med Assoc 1991;265: 70-73.
17. Mosher WD, Pratt WF. Contraceptive use in the United States, 1973-1988. Adv Data 1990;182:1-10.
18. Serfaty D. Medical aspects of oral contraceptive discontinuation. Adv Contracept 1992;8:21-33.
19. Robillard PY, Hulsey TC, Perianin J et al. Association of pregnancy-induced hypertension with duration of sexual cohabitation before conception. Lancet 1994;344:973-975.
20. Clark DA. Does immunological intercourse prevent preeclampsia. Lancet 1994;344:969-970.
21. Dekker GA. Oral tolerization to paternal antigens and preeclampsia (abstr). Am J Obstet Gynecol 1996;174:516.
22. Weiner HL, Friedman A, Miller A et al. Oral tolerance: Immunologic mechanisms and treatment of animal and human-organ specific autoimmune diseases by oral administration of autoantigens. Annu Rev Immunol 1994;12:809-837.
23. Mosmann TR, Cherwinski H, Bond MW. Two types of murine helper T cell clones. I. Definition according to profiles of lymphokine activities and secreted proteins. J Immunol 1986; 136:2348-2357.
24. Mosmann TR, Moore KW. The role of 11-10 in cross-regulation of TH1 and TH2 responses. Immunol Today 1991;12:A49-A53.
25. Wegmann TG, Lin H, Guilbert L et al. Bidirectional cytokine interactions in the maternal-fetal relationship: Is successful pregnancy a TH2 phenomenon? Immunol Today 1993;15: 353-356.
26. Marzi M, Vigano A, Trabattoni D et al. Characterization of type 1 and type 2 cytokine production profile in physiologic and pathologic human pregnancy. Clin Exp Immunol 1996;106: 127-133.
27. Schenker JG, Ezra Y. Complications of assisted reproductive techniques. Fertil Steril 1994;61:411-422.
28. Need JA, Bell B, Meffin E et al. Preeclampsia in pregnancies from donor inseminations. J Reprod Immunol 1983;5:329-338.
29. Grefenstette I, Royere D, Barthelemy CI et al. The outcome of 470 pregnancies obtained using AID with frozen semen. Eur J Obstet Gynecol Biol Reprod 1990;19:737-744.
30. Serhal PF, Craft I. Immune basis for preeclampsia: Evidence from oocyte recipients. Lancet 1987;2:744.
31. Serhal PF, Craft IL. Oocyte donation in 61 patients. Lancet 1989;1:1185-1187.
32. Pados G, Camus M, Van Steirteghem A et al. The evolution and outcome of pregnancies from oocyte donation. Hum Reprod 1994;9:538-542.
33. Soderstrom Anttila V, Hovatta O. An oocyte donation program with goserelin down-regulation of voluntary donors. Acta Obstet Gynecol Scand 1995;74:288-292.
34. Perkins RP. Pregnancy following donor insemination: Implications for preeclampsia. J Maternal Fetal Med 1993;2:52-54.
35. Friedman F Jr, Copperman AB, Brodman ML et al. Perinatal outcome after embryo transfer in ovum recipients: A comparison with standard in vitro fertilization. J Reprod Med 1996; 41:640-644.
36. Antinori S, Versaci C, Panci C et al. Fetal and maternal morbidity and mortality in menopausal women aged 45-63 years. Hum Reprod 1995;10:464-469.
37. Hendler I, Dulitzky M, Soriano D et al. Pregnancy outcome after oocyte donation. Am J Obstet Gynecol 1997;176:8133.
38. Michalas S, Loutradis D, Drakakis P et al. Oocyte donation to women over 40 years of age: Pregnancy complications. Eur J Obstet Gynecol Reprod Biol 1996;64:175-178.
39. Smarason AK, IL Sargent, PM Starkey et al. The effect of placental syncytiotrophoblast microvillous membranes from normal and preeclamptic women on the growth of endothelial cells in vivo. Br J Obstet Gynaecol 1993;100:943-949.
40. Zeeman GG, Dekker GA. Pathogenesis of preeclampsia: A hypothesis. Clin Obstet Gynecol 1992;35:317-337.
41. Dekker GA, van Geijn HP. Endothelial dysfunction in preeclampsia. Part I: Primary prevention. Therapeutic perspectives. J Perinat Med 1996;24:99-117.
42. Dekker GA, van Geijn HP. Endothelial dysfunction in preeclampsia. Part II: Reducing the adverse consequences of endothelial cell dysfunction in preeclampsia: Therapeutic perspectives. J Perinat Med 1996;24:119-139.
43. Beer AE, Need JA. Immunological Aspects of Preeclampsia/ Eclampsia. Birth Defects: Original Article Series, vol 21. BK Young, ed. 1985; pp 131-154.
44. Westendorp RG, Langermans JA, Huizinga TW et al. Genetic influence on cytokine production and fatal meningococcal disease. Lancet 1997;349:170-173.
45. Chen G, Wilson R, Wang SH et al. Tumor necrosis factor-alpha (TNF-α) gene polymorphism and expression in preeclampsia. Clin Exp Immunol 1996;104:154-159.
46. Haig D. Genetic conflicts in human pregnancy. Q Rev Biol 1993;68:495-532.
47. Letters to the Editor. Cohabitation and pregnancy-induced hypertension. Lancet 1994;344:1633-1636..